Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy

被引:49
作者
Srikanthan, Amirrtha [1 ]
Tran, Ben [1 ,5 ]
Beausoleil, Michel [2 ,3 ]
Jewett, Michael A. S. [1 ]
Hamilton, Robert J. [1 ]
Sturgeon, Jeremy F. G. [4 ]
O'Malley, Martin [1 ]
Anson-Cartwright, Lynn [1 ]
Chung, Peter W. M. [1 ]
Warde, Padraig R. [1 ]
Winquist, Eric [2 ,3 ]
Moore, Malcolm J. [1 ]
Amir, Eitan [1 ]
Bedard, Philippe L. [1 ]
机构
[1] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Western Ontario, London, ON, Canada
[3] London Hlth Sci Ctr, London, ON, Canada
[4] McGill Univ, Montreal, PQ, Canada
[5] Royal Melbourne Hosp, Melbourne, Vic, Australia
关键词
CLINICAL-PRACTICE GUIDELINES; GASTROINTESTINAL-TRACT; RECEIVING CHEMOTHERAPY; RISK-FACTORS; CANCER; PREVENTION; THROMBOSIS; PLACEBO; EVENTS; CISPLATIN;
D O I
10.1200/JCO.2014.58.6537
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Cisplatin-based chemotherapy, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous thromboembolism (VTE). Many patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may cause venous stasis and increase the risk of VTE development. We hypothesized that there was an association between large RPLN and chemotherapy-associated VTE risk. Patients and Methods The training cohort was composed of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Centre between January 2000 and December 2010. Large RPLN was defined as more than 5 cm in maximal axial diameter. The predictive and discriminatory accuracies of a model using large RPLN in predicting VTE were compared with high-risk Khorana score (>= 3) using logistic regression and area under receiver operator characteristic curves (AUROCs). The model was externally validated in a cohort of patients treated at the London Health Sciences Centre. Results The training cohort comprised 216 patients, 21 (10%) of whom developed VTE during chemotherapy. VTE was associated with large RPLN (odds ratio [OR], 5.26; P = .001), high-risk Khorana score (OR, 11.8; P < .001), intermediate-/poor-risk disease (OR, 3.76; P = .005), and hospitalization during chemotherapy (OR, 4.24; P = .002). Large RPLN showed higher discriminatory accuracy than high-risk Khorana score (AUROC, 0.71 v 0.67, respectively). Superior discriminatory accuracy of large RPLN over high-risk Khorana score was validated in the London cohort (AUROC, 0.61 v 0.57, respectively). Conclusion Large RPLN is associated with VTE in patients with disseminated GCT and provides higher discriminatory accuracy than high-risk Khorana score. Results should be validated in larger, prospective studies. Prophylactic anticoagulation may be considered in high-risk patients.
引用
收藏
页码:582 / U73
页数:8
相关论文
共 36 条
[1]   Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer [J].
Agnelli, Giancarlo ;
George, Daniel J. ;
Kakkar, Ajay K. ;
Fisher, William ;
Lassen, Michael R. ;
Mismetti, Patrick ;
Mouret, Patrick ;
Chaudhari, Umesh ;
Lawson, Francesca ;
Turpie, Alexander G. G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) :601-609
[2]   Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].
Agnelli, Giancarlo ;
Gussoni, Gualberto ;
Bianchini, Carlo ;
Verso, Melina ;
Mandala, Mario ;
Cavanna, Luigi ;
Barni, Sandra ;
Labianca, Roberto ;
Buzzi, Franco ;
Scambia, Giovanni ;
Passalacqua, Rodolfo ;
Ricci, Sergio ;
Gasparini, Giampietro ;
Lorusso, Vito ;
Bonizzoni, Erminio ;
Tonato, Maurizio .
LANCET ONCOLOGY, 2009, 10 (10) :943-949
[3]  
[Anonymous], 2014, NCCN Clinical Practice Guidelines in Oncology: Survivorship
[4]   Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer [J].
Beyer, J. ;
Albers, P. ;
Altena, R. ;
Aparicio, J. ;
Bokemeyer, C. ;
Busch, J. ;
Cathomas, R. ;
Cavallin-Stahl, E. ;
Clarke, N. W. ;
Classen, J. ;
Cohn-Cedermark, G. ;
Dahl, A. A. ;
Daugaard, G. ;
De Giorgi, U. ;
De Santis, M. ;
De Wit, M. ;
De Wit, R. ;
Dieckmann, K. P. ;
Fenner, M. ;
Fizazi, K. ;
Flechon, A. ;
Fossa, S. D. ;
Germa Lluch, J. R. ;
Gietema, J. A. ;
Gillessen, S. ;
Giwercman, A. ;
Hartmann, J. T. ;
Heidenreich, A. ;
Hentrich, M. ;
Honecker, F. ;
Horwich, A. ;
Huddart, R. A. ;
Kliesch, S. ;
Kollmannsberger, C. ;
Krege, S. ;
Laguna, M. P. ;
Looijenga, L. H. J. ;
Lorch, A. ;
Lotz, J. P. ;
Mayer, F. ;
Necchi, A. ;
Nicolai, N. ;
Nuver, J. ;
Oechsle, K. ;
Oldenburg, J. ;
Oosterhuis, J. W. ;
Powles, T. ;
Rajpert-De Meyts, E. ;
Rick, O. ;
Rosti, G. .
ANNALS OF ONCOLOGY, 2013, 24 (04) :878-888
[5]   Malignancies, prothrombotic mutations, and the risk of venous thrombosis [J].
Blom, JW ;
Doggen, CJM ;
Osanto, S ;
Rosendaal, FR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :715-722
[6]  
BREDAEL JJ, 1982, CANCER-AM CANCER SOC, V50, P548, DOI 10.1002/1097-0142(19820801)50:3<548::AID-CNCR2820500327>3.0.CO
[7]  
2-2
[8]   GASTROINTESTINAL-TRACT METASTASIS IN PATIENTS WITH GERM-CELL TUMOR OF TESTIS [J].
CHAIT, MM ;
KURTZ, RC ;
HAJDU, SI .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1978, 23 (10) :925-928
[9]  
Chew HK, 2006, ARCH INTERN MED, V166, P458
[10]   Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial [J].
Cohen, AT ;
Davidson, BL ;
Gallus, AS ;
Lassen, MR ;
Prins, MH ;
Tomkowski, W ;
Turpie, AGG ;
Egberts, JFM ;
Lensing, AWA .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7537) :325-327